CSMS, EAACI-ARIA allergy combined symptom-medication score; DATs, Digital adherence technologies; e-DASTHMA, Electronic daily control score for asthma; EMDs, Electronic monitoring devices; GDPR, General Data Protection Regulation; INCS, Inhaled corticosteroids; LABA, Long-acting b2 agonists; MART, MAintenance and Reliever Therapy; MASK-air, Mobile Airways Sentinel networK for airway diseases; MPR, Medication possession ratio; SABA, Short-acting beta-agonists; VAS, Visual analogue scale Asthma; Adherence; Inhaled corticosteroids; Formoterol; Long-acting-b2 agonist; Pulmonary and Respiratory Medicine
Abstract :
[en] Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting b2-agonists (ICS+LABA) in users of the MASK-air Ò app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air Ò data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication 80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Sousa-Pinto, B; MEDCIDS -Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal ; Faculty of Medicine, CINTESIS@RISE -Health Research Network, University of Porto, Porto, Portugal
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie ; Department of Pulmonary Medicine, CHU Li ege, Belgium ; GIGA I3 Research Group, University of Li ege, Belgium
Anto, J; ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain ; Universitat Pompeu Fabra (UPF), Barcelona, Spain ; CIBER Epidemiología y Salud P ublica (CIBERESP), Barcelona, Spain
Amaral, R; MEDCIDS -Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal ; Faculty of Medicine, CINTESIS@RISE -Health Research Network, University of Porto, Porto, Portugal
S A-Sousa, A
Czarlewski, W; MEDCIDS -Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal ; Faculty of Medicine, CINTESIS@RISE -Health Research Network, University of Porto, Porto, Portugal ; Medical Consulting Czarlewski, Levallois, France ; MASK-air, Montpellier, France
Brussino, L; MEDCIDS -Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal ; Department of Medical Sciences, University of Torino, Torino, Italy ; Allergy and Clinical Immunology Unit, Mauriziano Hospital, Torino, Italy
Canonica, G; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy ; IRCCS Humanitas Research Center, Rozzano, Italy
Chaves Loureiro, C; Department of Pneumology, University of Coimbra, Medicine Faculty, Coimbra, Portugal
Cruz, A; Fundaçao ProAR, GARD/WHO Planning Group, Federal University of Bahia, Salvador, Bahia, Brazil
Gemicioglu, B; Department of Pulmonary Diseases, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
Haahtela, T; Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland
Kupczyk, M; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
Kvedariene, V; Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania ; Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
Larenas-Linnemann, D; Center of Excellence in Asthma and Allergy, M edica Sur Clinical Foundation and Hospital, M exico City, Mexico
Okamoto, Y; Chiba Rosai Hospital, Chiba, Japan ; Chiba University Hospital, Chiba, Japan
Ollert, M; Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg ; Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark
Pfaar Z, O; Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universit€ at Marburg, Marburg, Germany aa ; Ecole Polytechnique de Palaiseau, Palaiseau, France bb ; IRBA (Institut de Recherche Bio-M edicale des Arm ees), Br etigny sur Orge, France cc ; Universit e Paris Cit e, Paris, France dd ; ee Allergy and Clinical Immunology Unit, IRCCS Humanitas Research Center, Personalized Medicine Asthma & Allergy, Rozzano, Italy ; ff Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine, Centro Hospitalar e Universit ario de Coimbra, Coimbra, Portugal ; Institute of Immunology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal gg ; University of Coimbra, Coimbra, Portugal ; Department of Allergology, ii Allergy Service, hh Medical University of Gda nsk, Gdansk, Poland ; jj PROMISE Department, Fundacion Jimenez Diaz, Autonoma University of Madrid, CIBERES-ISCIII, Madrid, Spain ; Department of Immunoallergology, University of Palermo, Palermo, Italy kk ; Cova da Beira University Hospital Centre, Covilhã, Portugal ll ; mm Allergy and Clinical Immunology, UBIAir -Clinical & Experimental Lung Centre and CICS-UBI Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal ; University of Bari Medical School, Bari, Italy ; Faculty of Medicine, nn Institute of Sciences of Food Production, National Research Council (ISPA-CNR), Bari, Italy oo ; Transylvania University of Brasov, Brasov, Romania ; Department of Otorhinolaryngology, pp ARIA, Montpellier, France qq ; University of T€ ubingen, T€ ubingen, Germany ; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, tt Quality Use of Respiratory Medicines Group, rr Institute of Allergology, Charit e À Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and Humboldt-Universit€ at zu Berlin, Berlin, Berlin, Germany ss, Germany ; uu Macquarie Medical School, Woolcock Institute of Medical Research, Sydney, Australia ; vv Department of Cardiovascular and Respiratory Sciences, Macquarie University, Macquarie Park, Australia ; Department of Neurological, Universita Cattolica del Sacro Cuore, Rome, Italy ww ; ENT and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli -IRCCS, Rome, Italy ; xx National Heart and Lung Institute (NHLI), Imperial College London, London, UK ; Department of Respiratory Medicine, yy Quebec Heart and Lung Institute, Laval University, Quebec City, Canada zz ; Department of Pulmonary Medicine, Ghent University Hospital, Ghent, Belgium aaa ; Mainz University Hospital, Mainz, Germany ; bbb SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy ; ccc Clinique des Bronches, Allergie et Sommeil, Hôpital Nord, Marseille, France ; Chest Disease Department, Federation of Translational Medicine, ddd Allergy Division, University Hospital of Strasbourg, Strasbourg, France eee ; Public Health and Unit of Allergy and Clinical Immunology, Department of Medical Sciences, University of Strasbourg, Strasbourg, France fff ; University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy ; Department of Clinical Immunology, ggg Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina hhh ; Wroc»aw Medical University, Wroclaw, Poland ; Department of Otolaryngology, Head and Neck Surgery, iii ALL-MED Medical Research Institute, Wroclaw, Poland jjj ; Center for Rhinology and Allergology, Department of Otorhinolaryngology, Head and Neck Surgery, Universit€ atsmedizin Mainz, Mainz, Wiesbaden, Germany kkk, Germany lll ; Semmelweis University, Budapest, Hungary ; mmm KYomed INNOV, Montpellier, France ; nnn Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal ooo ; Universit e Paris-Saclay, UVSQ, Univ. Paris-Sud, Villejuif, France ppp Inserm ; Equipe d'Epid emiologie Respiratoire Int egrative, CESP, Villejuif, France
Pham-Thi Aa, N
Regateiro, F
Romantowski Hh, J
Sastre Ii, J
Scichilone Jj, N
Taborda-Barata, L
Ventura, M
Agache, I
Bedbrook, A; MASK-air, Montpellier, France
Becker Qq, S
Bergmann, K
Bosnic-Anticevich, S
Bonini, M
Boulet Yy, L.-P
Brusselle Zz, G
Buhl Aaa, R
Cecchi Bbb, L
Charpin Ccc, D
De Blay, F
Giacco, S
Ivancevich, J
Jutel, M
Klimek, L
Kraxner Lll, H
Kuna, P; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
Laune, D
Makela, M; Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland
Morais-Almeida, M
Nadif, R
Niedoszytko Qqq, M
Papadopoulos, N
Papi, A
Patella, V
Pétré, Benoît ; Université de Liège - ULiège > Département des sciences de la santé publique > Education thérapeutique du patient au service des soins intégrés
EIT Health AHA - American Heart Association EC - European Commission
Funding text :
MASK-air has been supported by EU grants (POLLAR, EITHealth; Structural and Development Funds, Twinning, EIP on AHA, H2020 and Horizon Europe) and by educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach.There was no specific funding for this paper.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43:2 (2014), 343–373, 10.1183/09031936.00202013.
Jansen, EM, van de Hei, SJ, Dierick, BJH, Kerstjens, HAM, Kocks, JWH, van Boven, JFM., Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. J Thorac Dis 13:6 (2021), 3846–3864, 10.21037/jtd-20-2360.
McDonald, VM, Yorke, J, Adherence in severe asthma: time to get it right. Eur Respir J, 50(6), 2017, 1702191, 10.1183/13993003.02191-2017.
Huvanandana, J, Nguyen, CD, Foster, JM, Frey, U, Reddel, HK, Thamrin, C., Novel methods of measuring adherence patterns reveal adherence phenotypes with distinct asthma outcomes. Ann Am Thorac Soc 19:6 (2022), 933–942, 10.1513/AnnalsATS.202106-653OC.
Riley, IL, Jackson, B, Crabtree, D, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. J Allergy Clin Immunol Pract 9:1 (2021), 410–418, 10.1016/j.jaip.2020.08.021 e4.
Tibble, H, Flook, M, Sheikh, A, et al. Measuring and reporting treatment adherence: what can we learn by comparing two respiratory conditions?. Br J Clin Pharmacol 87:3 (2021), 825–836, 10.1111/bcp.14458.
Hew, M, Reddel, HK, Integrated adherence monitoring for inhaler medications. JAMA 321:11 (19 2019), 1045–1046, 10.1001/jama.2019.1289.
Nguyen, E, Miao, B, Pugliese, N, Huang, D, Sobieraj, DM, Systematic review of mHealth applications that interface with inhaler sensors in asthma. J Allergy Clin Immunol Pract 9:2 (2021), 844–852, 10.1016/j.jaip.2020.08.049 e3.
Chan, AH, Harrison, J, Black, PN, Mitchell, EA, Foster, JM, Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract 3:3 (2015), 335–349, 10.1016/j.jaip.2015.01.024 e1-5.
Moore, A, Preece, A, Sharma, R, et al. A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. Eur Respir J, 57(6), 2021, 2003103, 10.1183/13993003.03103-2020.
Harada, N, Harada, S, Ito, J, Atsuta, R, Hori, S, Takahashi, K, Mobile health app for Japanese adult patients with asthma: clinical observational study. J Med Internet Res, 22(8), 14 2020, e19006, 10.2196/19006.
Murphy, J, McSharry, J, Hynes, L, Molloy, GJ, A smartphone app to support adherence to inhaled corticosteroids in young adults with asthma: multi-methods feasibility study. JMIR Form Res, 5(9), 2021, e28784, 10.2196/28784.
Jacome, C, Almeida, R, Pereira, AM, et al. Feasibility and acceptability of an asthma app to monitor medication adherence: mixed methods study. JMIR Mhealth Uhealth, 9(5), 2021, e26442, 10.2196/26442.
Jacome, C, Pereira, R, Almeida, R, et al. Validation of app and phone versions of the control of allergic rhinitis and asthma test (CARAT). J Investig Allergol Clin Immunol 31:3 (2021), 270–273, 10.18176/jiaci.0640.
Kaye, L, Gondalia, R, Thompson, A, Stempel, DA, Barrett, MA, The relationship between objective app engagement and medication adherence in asthma and COPD: a retrospective analysis. Sci Rep, 11(1), 2021, 24343, 10.1038/s41598-021-03827-2.
Menditto, E, Costa, E, Midao, L, et al. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. Clin Exp Allergy 49:4 (2019), 442–460, 10.1111/cea.13333.
Bousquet, J, Arnavielhe, S, Bedbrook, A, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy, 8, 2018, 45, 10.1186/s13601-018-0227-6.
Laune, D, Arnavielhe, S, Viart, F, et al. [Adaptation of the General Data Protection Regulation (GDPR) to a smartphone app for rhinitis and asthma (MASK-air(R))]. Rev Mal Respir 36:9 (2019), 1019–1031, 10.1016/j.rmr.2019.08.003 Reglement general sur la protection des donnees pour MASK-air(R) (application mobile rhinite et asthme).
Bousquet, J, Agache, I, Aliberti, MR, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA). Allergy 73:1 (2017), 77–92, 10.1111/all.13218.
Sousa-Pinto, B, Azevedo, LF, Jutel, M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. Allergy 77:7 (2022), 2147–2162, 10.1111/all.15199.
Sousa-Pinto, B, Jacome, C, Perreira, A, et al. Development and validation of an electronic daily control score for asthma (e-DASTHMA). Lancet Digital Health 5:4 (2023), e227–e238, 10.1016/S2589-7500(23)00020-1.
Cohen, J, Statistical Power Analysis for the Behavioral Sciences. 1988, Taylor and Francis Group, 567, 10.4324/9780203771587.
Sedgwick, P, Bias in observational study designs: prospective cohort studies. BMJ, 349, 2014, g7731, 10.1136/bmj.g7731.
Bousquet, J, Sousa-Pinto, B, et al. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app. Pulmonology 29:4 (2023), 292–305, 10.1016/j.pulmoe.2022.10.005.
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Reddel, HK, FitzGerald, JM, Bateman, ED, et al. (eds.) Eur Respir J, 53(6), 2019, 1901046, 10.1183/13993003.01046-2019.
O'Byrne, PM, FitzGerald, JM, Bateman, ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 378:20 (2018), 1865–1876, 10.1056/NEJMoa1715274.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
